MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells
- PMID: 29893623
- PMCID: PMC6080116
- DOI: 10.1089/nat.2017.0695
MIS416 as a siRNA Delivery System with the Ability to Target Antigen-Presenting Cells
Abstract
MIS416 is a microparticulate formulation derived from propionibacterium acnes cell wall skeletons with intrinsic adjuvant activity. Conjugates of MIS416-SS-peptide containing a disulfide linkage facilitate the cytoplasmic delivery and release of peptides in antigen-presenting cells (APCs). We hypothesized that MIS416-siRNA (small interfering RNA) conjugates, containing a disulfide linkage between MIS416 and the siRNA, would allow cytoplasmic release of siRNA in APCs. MIS416-SS-siStat3 conjugates added to cell culture medium of monolayers of DCs in culture flasks successfully targeted Stat3 mRNA in DCs in vitro without transfection, downregulating Stat3 mRNA and protein levels. These results suggest that MIS416-SS-siRNA conjugates can be used as a novel siRNA delivery system for the knockdown of mRNA levels in APCs.
Keywords: Stat3; delivery; dendritic cells; gene silencing; siRNA.
Conflict of interest statement
F.M., D.S.L., S.Y., and M.R.E. have no competing financial interests. G.A.W. is Chief Scientific Officer of Innate Immunotherapeutics Limited.
Figures



Similar articles
-
Bridging Small Molecules to Modified Bacterial Microparticles Using a Disulphide Linkage: MIS416 as a Cargo Delivery System.PLoS One. 2015 Dec 22;10(12):e0145403. doi: 10.1371/journal.pone.0145403. eCollection 2015. PLoS One. 2015. PMID: 26695183 Free PMC article.
-
STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response.Mol Pharm. 2010 Oct 4;7(5):1643-54. doi: 10.1021/mp100067u. Epub 2010 Sep 14. Mol Pharm. 2010. PMID: 20804176
-
MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity.Vaccine. 2011 Jan 10;29(3):545-57. doi: 10.1016/j.vaccine.2010.10.040. Epub 2010 Oct 27. Vaccine. 2011. PMID: 21034827
-
Engineering better immunotherapies via RNA interference.Hum Vaccin Immunother. 2014;10(11):3165-74. doi: 10.4161/hv.29754. Hum Vaccin Immunother. 2014. PMID: 25483669 Free PMC article. Review.
-
Journey of siRNA: Clinical Developments and Targeted Delivery.Nucleic Acid Ther. 2018 Aug;28(4):209-224. doi: 10.1089/nat.2017.0715. Epub 2018 Mar 27. Nucleic Acid Ther. 2018. PMID: 29584585 Review.
Cited by
-
Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy.Molecules. 2020 Jun 10;25(11):2692. doi: 10.3390/molecules25112692. Molecules. 2020. PMID: 32532030 Free PMC article. Review.
-
Strategies to improve the effect of mesenchymal stem cell therapy on inflammatory bowel disease.World J Stem Cells. 2022 Sep 26;14(9):684-699. doi: 10.4252/wjsc.v14.i9.684. World J Stem Cells. 2022. PMID: 36188115 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous